RETA

Reata Pharmaceuticals, Inc. (RETA) | Rumor.io

Reata Pharmaceuticals

RETA

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about RETA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jan 10

$RETA is gaining popularity among the younger generation, potentially leading to increased demand and prices.
The asset is being compared to Ozempic, suggesting it may have similar use cases or applications.
Holders and traders are optimistic about the asset's future, with some predicting it will trend and become a "norm" among Gen Z.

Generated by AI

Sentiment

Of the messages about RETA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	99.07% +27.18
Bearish	—	—	0%	0.93% -27.18

Bullish· Jul 28

$RETA has been acquired by Biogen in a $7.3 billion deal, with a $172.50 per share price, representing a 59% premium to its previous close.
The acquisition is expected to close in Q4 2023 and will likely provide a boost to late-stage biotechs tackling hard-to-treat and/or cure diseases.
The company's lead product, SKYCLARYS, is the first and only approved treatment for Friedreich's ataxia, and its commercial launch is expected to be a significant contributor to the company's growth.

Bearish· Jul 28

$RETA's high short interest of 14% could lead to significant selling pressure if the stock continues to decline.
Insiders have been selling Reata Pharmaceuticals stock throughout the year, which may be a sign of decreased confidence in the company's prospects.
The stock's recent halt and downgrade by multiple analysts, including Cantor Fitzgerald, Stifel Nicolaus, and Jefferies Financial Group Inc., suggests that the market is increasingly bearish on Reata Pharmaceuticals.

Generated by AI

Topics

Of the messages about RETA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	—	—	—	47.83%
Macro	—	—	—	0%
Earnings	—	—	—	0%
Controversies	—	—	—	0%
Announcements	—	—	—	52.17%
Analysts	—	—	—	0%

Earnings· Nov 13

Reata Pharmaceuticals, Inc. ($RETA) missed earnings estimates by $0.09, but beat revenue expectations.
The company's loss per share was worse than predicted, while its revenue came in line with forecasts.
The earnings miss and beat on revenue were reported in the premarket session.

Analysts· Mar 1

Reata Pharmaceuticals' price target was raised by several analysts, including Citi to $120, Goldman Sachs to $185, Barclays to $90, and Cantor Fitzgerald to $121.
Analysts maintain a strong buy consensus on the stock, with 85% of analysts recommending a buy, and many have raised their price targets following the FDA approval of Skyclarys.
The stock has significant short interest, with 32% of float short, but analysts believe it is still undervalued and has the potential to exceed its current price target.

Announcements· Jul 28

Biogen has agreed to acquire Reata Pharmaceuticals for $172.50 per share in cash, representing an enterprise value of approximately $7.3 billion.
The acquisition is a 58.9% premium to Reata's previous closing price and is expected to be completed in the coming months.
Reata's shareholders will receive $172.50 per share in cash, with the company's shares halted pending the completion of the acquisition.

Technical Analysis· Mar 2

$RETA has a double top at $87.50 zone and is forming a head and shoulders pattern, potentially leading to a low in the 70s.
The stock has a break above $87.50 that could open the door to a gap fill to $93.
$RETA is showing strength, with dips being bought and the stock holding $90 well, potentially setting up a gap up tomorrow.

Generated by AI

Community

Of the messages about RETA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	53.93%
Newcomers	—	—	0%	46.07%

Regulars· Jul 28

Biogen is acquiring Reata Pharmaceuticals in a $7 billion deal, with a price of $172.50 per share.
The acquisition is a significant premium, with Reata Pharmaceuticals' stock price increasing by over 50% in a single day.
The deal highlights Biogen's focus on rare disease, immunology, and neuropsychiatry, areas where Reata Pharmaceuticals' technology can be applied.

Newcomers· Aug 2

New traders are learning about options trading and strategies, such as strangles and spreads, through online resources like YouTube videos.
Observant traders are using flow analysis to identify heavy buying and selling activity, which can indicate where insider traders are placing their bets.
Concerns are being raised about insider trading, with some users questioning how certain individuals had prior knowledge of the Reata acquisition.

Generated by AI

Also Discussed

Investors talking about RETA also mention

#	Name	Attention
1	MRTX - Mirati Therapeutics, Inc.	——
2	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02
3	FGEN - FibroGen, Inc.	——
4	KRTX - Karuna Therapeutics, Inc.	——
5	Amylyx Pharmaceuticals, Inc.AMLX	0%+0
6	SWTX - SpringWorks Therapeutics, Inc.	——
7	DICE - DICE Therapeutics, Inc.	——
8	ETNB - 89bio, Inc.	——
9	Alnylam Pharmaceuticals, Inc.ALNY	0%0
10	HPX - HPX Corp.	——